<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">100883818</journal-id>
<journal-id journal-id-type="pubmed-jr-id">26775</journal-id>
<journal-id journal-id-type="nlm-ta">Value Health</journal-id>
<journal-id journal-id-type="iso-abbrev">Value Health</journal-id>
<journal-title-group>
<journal-title>Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research</journal-title>
</journal-title-group>
<issn pub-type="ppub">1098-3015</issn>
<issn pub-type="epub">1524-4733</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30224106</article-id>
<article-id pub-id-type="pmc">6159915</article-id>
<article-id pub-id-type="doi">10.1016/j.jval.2018.06.017</article-id>
<article-id pub-id-type="manuscript">NIHMS985392</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Methodological Issues in Assessing the Economic Value of Next-Generation Sequencing Tests: Many Challenges and Not Enough Solutions</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Phillips</surname>
<given-names>Kathryn A.</given-names>
</name>
<degrees>PhD</degrees>
<aff id="A1">University of California at San Francisco, Department of Clinical Pharmacy; Center for Translational and Policy Research on Personalized Medicine (TRANSPERS); UCSF Philip R. Lee Institute for Health Policy; and UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA</aff>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Deverka</surname>
<given-names>Patricia A.</given-names>
</name>
<degrees>MD, MS</degrees>
<aff id="A2">American Institutes for Research, Chapel Hill, NC, USA</aff>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Marshall</surname>
<given-names>Deborah A</given-names>
</name>
<degrees>PhD</degrees>
<aff id="A3">Department of Community Health Sciences, University of Calgary, Calgary, Alberta T2N 4Z6, Canada</aff>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wordsworth</surname>
<given-names>Sarah</given-names>
</name>
<degrees>PhD</degrees>
<aff id="A4">Nuffield Department of Population Health, Medical Sciences Division, University of Oxford, Oxford, United Kingdom</aff>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Regier</surname>
<given-names>Dean A.</given-names>
</name>
<degrees>PhD</degrees>
<aff id="A5">Cancer Control BC, School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada</aff>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Christensen</surname>
<given-names>Kurt D.</given-names>
</name>
<degrees>PhD</degrees>
<aff id="A6">Brigham and Womenâ€™s Hospital, Harvard University, Boston, MA, USA</aff>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Buchanan</surname>
<given-names>James</given-names>
</name>
<degrees>DPhil</degrees>
<aff id="A7">Nuffield Department of Population Health, Medical Sciences Division, University of Oxford, Oxford, United Kingdom</aff>
</contrib>
</contrib-group>
<author-notes>
<corresp id="CR1"><bold>Contact Information for Corresponding Author: Kathryn A. Phillips, PhD</bold>, University of California at San Francisco, Department of Clinical Pharmacy; Center for Translational and Policy Research on Personalized Medicine (TRANSPERS); UCSF Philip R. Lee Institute for Health Policy; and UCSF Helen Diller Family Comprehensive Cancer Center, 3333 California St, Room 420, Box 0613, San Francisco, CA 94143, USA, Tel: (415) 502-4025, Fax: (415) 502-0792, <email>Kathryn.Phillips@ucsf.edu</email></corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>16</day>
<month>8</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>08</day>
<month>8</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="ppub">
<month>9</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>27</day>
<month>9</month>
<year>2018</year>
</pub-date>
<volume>21</volume>
<issue>9</issue>
<fpage>1033</fpage>
<lpage>1042</lpage>
<!--elocation-id from pubmed: 10.1016/j.jval.2018.06.017-->
<abstract id="ABS1">
<sec id="S2">
<title>Background</title>
<p id="P1">Clinical use of next-generation sequencing (NGS) tests has been increasing, but few studies have examined their economic value. Several studies have noted that there are methodological challenges to conducting economic evaluations of NGS tests.</p>
</sec>
<sec id="S3">
<title>Objective</title>
<p id="P2">Our objective was to examine key methodological challenges for conducting economic evaluations of NGS tests, prioritize these challenges for future research, and identify how studies have attempted solutions to address these challenges.</p>
</sec>
<sec id="S4">
<title>Methods</title>
<p id="P3">We identified challenges for economic evaluations of NGS tests using prior literature and expert judgment of the co-authors. We used a modified Delphi assessment to prioritize challenges, based on importance and probability of resolution. Using a structured literature review and article extraction we then assessed whether published economic evaluations had addressed these challenges.</p>
</sec>
<sec id="S5">
<title>Results</title>
<p id="P4">We identified 11 challenges for conducting economic evaluations of NGS tests. The experts identified three challenges as the top priorities for future research: complex model structure, timeframe, and type of analysis and comparators used. Of the 15 published studies included in our literature review, four studies described specific solutions relevant to five of the 11 identified challenges.</p>
</sec>
<sec id="S6">
<title>Conclusions</title>
<p id="P5">Major methodological challenges to economic evaluations of NGS tests remain to be addressed. Our results can be used to guide future research and inform decision-makers on how to prioritize research on the economic assessment of NGS tests</p>
</sec>
</abstract>
<abstract abstract-type="summary" id="ABS2">
<title>Precis</title>
<p id="P6">We examine methodological challenges for conducting economic evaluations of next generation sequencing tests, prioritize these challenges, and identify how studies have applied solutions.</p>
</abstract>
</article-meta>
</front>
</article>
</pmc-articleset>